Trial reportProceedings of the National Academy of Sciences of the United States of America1996
Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy.
Trial report in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 152 citations in OpenAlex.
- Chemoprotection of murine hematopoietic cells by combined gene transfer of cytidine deaminase (CDD) and multidrug resistance 1 gene (MDR1).Journal of experimental & clinical cancer research : CR · 2015Article
- Is cancer gene therapy an empty suit?The Lancet. Oncology · 2013Review
- F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.Cancer gene therapy · 2012Article
- Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.Antioxidants & redox signaling · 2009Review
- Genetic modification of human hematopoietic cells: preclinical optimization of oncoretroviral-mediated gene transfer for clinical trials.Methods in molecular biology (Clifton, N.J.) · 2009Article
- Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients.Cancer science · 2007Article
- Article
- Gene therapy with drug resistance genes.Cancer gene therapy · 2006Review
- Review
- A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition.Cancer gene therapy · 2005Article
- Article
- Hematopoietic stem cell gene therapy: progress toward therapeutic targets.Bone marrow transplantation · 2003Review
- Clinical application of hematopoietic progenitor cell expansion: current status and future prospects.Bone marrow transplantation · 2003Review
- Topical colchicine selection of keratinocytes transduced with the multidrug resistance gene (MDR1) can sustain and enhance transgene expression in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- In vivo selective expansion of gene-modified hematopoietic cells in a nonhuman primate model.Gene therapy · 2002Article
- Genetic marking as an approach to studying in vivo hematopoiesis: progress in the non-human primate model.Oncogene · 2002Review
- Hematopoietic stem cell gene therapy.International journal of hematology · 2002Review
- Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow.Proceedings of the National Academy of Sciences of the United States of America · 2002Article
- Efficient retrovirus-mediated transduction of primitive human peripheral blood progenitor cells in stroma-free suspension culture.Gene therapy · 2001Article
- Clinical gene therapy in hematology: past and future.International journal of hematology · 2001Review
Corrections and comments
- Erratum issued
Authors and funding
25 authors at 4 institutions in 1 country.
Funding
Abstract
To formally test the hypothesis that the granulocyte/macrophage colony-forming unit (GM-CFU) cells can contribute to early hematopoietic reconstitution immediately after transplant, the frequency of genetically modified GM-CFU after retroviral vector transduction was measured by a quantitative in situ polymerase chain reaction (PCR), which is specific for the multidrug resistance-1 (MDR-1) vector, and by a quantitative GM-CFU methylcellulose plating assay. The results of this analysis showed no difference between the transduction frequency in the products of two different transduction protocols: "suspension transduction" and "stromal growth factor transduction." However, when an analysis of the frequency of cells positive for the retroviral MDR-1 vector posttransplantation was carried out, 0 of 10 patients transplanted with cells transduced by the suspension method were positive for the vector MDR-1 posttransplant, whereas 5 of 8 patients transplanted with the cells transduced by the stromal growth factor method were positive for the MDR-1 vector transcription unit by in situ or in solution PCR assay (a difference that is significant at the P = 0.0065 level by the Fisher exact test). These data suggest that only very small subsets of the GM-CFU fraction of myeloid cells, if any, contribute to the repopulation of the hematopoietic tissues that occurs following intensive systemic therapy and transplantation of autologous hematopoietic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.